schliessen

Filtern

 

Bibliotheken

The therapeutic efficacy of camptothecin-encapsulated supramolecular nanoparticles

Nanomaterials have been increasingly employed as drug(s)-incorporated vectors for drug delivery due to their potential of maximizing therapeutic efficacy while minimizing systemic side effects. However, there have been two main challenges for these vectors: (i) the existing synthetic approaches are... Full description

Journal Title: Biomaterials February 2012, Vol.33(4), pp.1162-1169
Main Author: Chen, Kuan-Ju
Other Authors: Tang, Li , Garcia, Mitch André , Wang, Hao , Lu, Hua , Lin, Wei-Yu , Hou, Shuang , Yin, Qian , Shen, Clifton K.-F. , Cheng, Jianjun , Tseng, Hsian-Rong
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0142-9612 ; DOI: 10.1016/j.biomaterials.2011.10.044
Link: http://dx.doi.org/10.1016/j.biomaterials.2011.10.044
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: sciversesciencedirect_elsevierS0142-9612(11)01248-8
title: The therapeutic efficacy of camptothecin-encapsulated supramolecular nanoparticles
format: Article
creator:
  • Chen, Kuan-Ju
  • Tang, Li
  • Garcia, Mitch André
  • Wang, Hao
  • Lu, Hua
  • Lin, Wei-Yu
  • Hou, Shuang
  • Yin, Qian
  • Shen, Clifton K.-F.
  • Cheng, Jianjun
  • Tseng, Hsian-Rong
subjects:
  • Supramolecular Assembly
  • Nanoparticles
  • Drug Delivery
  • Positron Emission Tomography
  • Cancer Therapeutics
ispartof: Biomaterials, February 2012, Vol.33(4), pp.1162-1169
description: Nanomaterials have been increasingly employed as drug(s)-incorporated vectors for drug delivery due to their potential of maximizing therapeutic efficacy while minimizing systemic side effects. However, there have been two main challenges for these vectors: (i) the existing synthetic approaches are cumbersome and incapable of achieving precise control of their structural properties, which will affect their biodistribution and therapeutic efficacies, and (ii) lack of an early checkpoint to quickly predict which drug(s)-incorporated vectors exhibit optimal therapeutic outcomes. In this work, we utilized a new rational developmental approach to rapidly screen nanoparticle (NP)-based cancer therapeutic agents containing a built-in companion diagnostic utility for optimal therapeutic efficacy. The approach leverages the advantages of a self-assembly synthetic method for preparation of two different sizes of drug-incorporated supramolecular nanoparticles (SNPs), and a positron emission tomography (PET) imaging-based biodistribution study to quickly evaluate the accumulation of SNPs at a tumor site in vivo and select the favorable SNPs for in vivo therapeutic study. Finally, the enhanced in vivo anti-tumor efficacy of the selected SNPs was validated by tumor reduction/inhibition studies. We foresee our rational developmental approach providing a general strategy in the search of optimal therapeutic agents among the diversity of NP-based therapeutic agents.
language: eng
source:
identifier: ISSN: 0142-9612 ; DOI: 10.1016/j.biomaterials.2011.10.044
fulltext: fulltext
issn:
  • 01429612
  • 0142-9612
url: Link


@attributes
ID778854135
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordidS0142-9612(11)01248-8
sourceidsciversesciencedirect_elsevier
recordidTN_sciversesciencedirect_elsevierS0142-9612(11)01248-8
sourcesystemOther
pqid905680913
galeid272905965
display
typearticle
titleThe therapeutic efficacy of camptothecin-encapsulated supramolecular nanoparticles
creatorChen, Kuan-Ju ; Tang, Li ; Garcia, Mitch André ; Wang, Hao ; Lu, Hua ; Lin, Wei-Yu ; Hou, Shuang ; Yin, Qian ; Shen, Clifton K.-F. ; Cheng, Jianjun ; Tseng, Hsian-Rong
ispartofBiomaterials, February 2012, Vol.33(4), pp.1162-1169
identifierISSN: 0142-9612 ; DOI: 10.1016/j.biomaterials.2011.10.044
subjectSupramolecular Assembly ; Nanoparticles ; Drug Delivery ; Positron Emission Tomography ; Cancer Therapeutics
descriptionNanomaterials have been increasingly employed as drug(s)-incorporated vectors for drug delivery due to their potential of maximizing therapeutic efficacy while minimizing systemic side effects. However, there have been two main challenges for these vectors: (i) the existing synthetic approaches are cumbersome and incapable of achieving precise control of their structural properties, which will affect their biodistribution and therapeutic efficacies, and (ii) lack of an early checkpoint to quickly predict which drug(s)-incorporated vectors exhibit optimal therapeutic outcomes. In this work, we utilized a new rational developmental approach to rapidly screen nanoparticle (NP)-based cancer therapeutic agents containing a built-in companion diagnostic utility for optimal therapeutic efficacy. The approach leverages the advantages of a self-assembly synthetic method for preparation of two different sizes of drug-incorporated supramolecular nanoparticles (SNPs), and a positron emission tomography (PET) imaging-based biodistribution study to quickly evaluate the accumulation of SNPs at a tumor site in vivo and select the favorable SNPs for in vivo therapeutic study. Finally, the enhanced in vivo anti-tumor efficacy of the selected SNPs was validated by tumor reduction/inhibition studies. We foresee our rational developmental approach providing a general strategy in the search of optimal therapeutic agents among the diversity of NP-based therapeutic agents.
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://dx.doi.org/10.1016/j.biomaterials.2011.10.044$$EView_record_in_ScienceDirect
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Chen, Kuan-Ju
1Tang, Li
2Garcia, Mitch André
3Wang, Hao
4Lu, Hua
5Lin, Wei-Yu
6Hou, Shuang
7Yin, Qian
8Shen, Clifton K.-F.
9Cheng, Jianjun
10Tseng, Hsian-Rong
titleThe therapeutic efficacy of camptothecin-encapsulated supramolecular nanoparticles
descriptionNanomaterials have been increasingly employed as drug(s)-incorporated vectors for drug delivery due to their potential of maximizing therapeutic efficacy while minimizing systemic side effects. However, there have been two main challenges for these vectors: (i) the existing synthetic approaches are cumbersome and incapable of achieving precise control of their structural properties, which will affect their biodistribution and therapeutic efficacies, and (ii) lack of an early checkpoint to quickly predict which drug(s)-incorporated vectors exhibit optimal therapeutic outcomes. In this work, we utilized a new rational developmental approach to rapidly screen nanoparticle (NP)-based cancer therapeutic agents containing a built-in companion diagnostic utility for optimal therapeutic efficacy. The approach leverages the advantages of a self-assembly synthetic method for preparation of two different sizes of drug-incorporated supramolecular nanoparticles (SNPs), and a positron emission tomography (PET) imaging-based biodistribution study to quickly evaluate the accumulation of SNPs at a tumor site in vivo and select the favorable SNPs for in vivo therapeutic study. Finally, the enhanced in vivo anti-tumor efficacy of the selected SNPs was validated by tumor reduction/inhibition studies. We foresee our rational developmental approach providing a general strategy in the search of optimal therapeutic agents among the diversity of NP-based therapeutic agents.
subject
0Supramolecular Assembly
1Nanoparticles
2Drug Delivery
3Positron Emission Tomography
4Cancer Therapeutics
general
0English
1Elsevier Ltd
210.1016/j.biomaterials.2011.10.044
3ScienceDirect (Elsevier B.V.)
4ScienceDirect Journals (Elsevier)
sourceidsciversesciencedirect_elsevier
recordidsciversesciencedirect_elsevierS0142-9612(11)01248-8
issn
001429612
10142-9612
rsrctypearticle
creationdate2012
addtitleBiomaterials
searchscope
0sciversesciencedirect_elsevier
1elsevier_sciencedirect
scope
0sciversesciencedirect_elsevier
1elsevier_sciencedirect
startdate20120201
enddate20120231
citationpf 1162 pt 1169 vol 33 issue 4
lsr30VSR-Enriched:[pqid, galeid, eissn]
sort
titleThe therapeutic efficacy of camptothecin-encapsulated supramolecular nanoparticles
authorChen, Kuan-Ju ; Tang, Li ; Garcia, Mitch André ; Wang, Hao ; Lu, Hua ; Lin, Wei-Yu ; Hou, Shuang ; Yin, Qian ; Shen, Clifton K.-F. ; Cheng, Jianjun ; Tseng, Hsian-Rong
creationdate20120200
lso0120120200
facets
frbrgroupid6062583747096293930
frbrtype5
languageeng
creationdate2012
topic
0Supramolecular Assembly
1Nanoparticles
2Drug Delivery
3Positron Emission Tomography
4Cancer Therapeutics
collectionScienceDirect Journals (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Chen, Kuan-Ju
1Tang, Li
2Garcia, Mitch André
3Wang, Hao
4Lu, Hua
5Lin, Wei-Yu
6Hou, Shuang
7Yin, Qian
8Shen, Clifton K.-F.
9Cheng, Jianjun
10Tseng, Hsian-Rong
jtitleBiomaterials
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Chen
1Tang
2Garcia
3Wang
4Lu
5Lin
6Hou
7Yin
8Shen
9Cheng
10Tseng
aufirstKuan-Ju
au
0Chen, Kuan-Ju
1Tang, Li
2Garcia, Mitch André
3Wang, Hao
4Lu, Hua
5Lin, Wei-Yu
6Hou, Shuang
7Yin, Qian
8Shen, Clifton K.-F.
9Cheng, Jianjun
10Tseng, Hsian-Rong
atitleThe therapeutic efficacy of camptothecin-encapsulated supramolecular nanoparticles
jtitleBiomaterials
risdate201202
volume33
issue4
spage1162
epage1169
pages1162-1169
issn0142-9612
formatjournal
genrearticle
ristypeJOUR
abstractNanomaterials have been increasingly employed as drug(s)-incorporated vectors for drug delivery due to their potential of maximizing therapeutic efficacy while minimizing systemic side effects. However, there have been two main challenges for these vectors: (i) the existing synthetic approaches are cumbersome and incapable of achieving precise control of their structural properties, which will affect their biodistribution and therapeutic efficacies, and (ii) lack of an early checkpoint to quickly predict which drug(s)-incorporated vectors exhibit optimal therapeutic outcomes. In this work, we utilized a new rational developmental approach to rapidly screen nanoparticle (NP)-based cancer therapeutic agents containing a built-in companion diagnostic utility for optimal therapeutic efficacy. The approach leverages the advantages of a self-assembly synthetic method for preparation of two different sizes of drug-incorporated supramolecular nanoparticles (SNPs), and a positron emission tomography (PET) imaging-based biodistribution study to quickly evaluate the accumulation of SNPs at a tumor site in vivo and select the favorable SNPs for in vivo therapeutic study. Finally, the enhanced in vivo anti-tumor efficacy of the selected SNPs was validated by tumor reduction/inhibition studies. We foresee our rational developmental approach providing a general strategy in the search of optimal therapeutic agents among the diversity of NP-based therapeutic agents.
pubElsevier Ltd
doi10.1016/j.biomaterials.2011.10.044
eissn18785905
date2012-02